EP 3253769 B1 20190313 - NOVEL POLYMORPHS
Title (en)
NOVEL POLYMORPHS
Title (de)
NEUARTIGE POLYMORPHE
Title (fr)
NOUVEAUX POLYMORPHES
Publication
Application
Priority
- EP 15153961 A 20150205
- EP 2016051691 W 20160127
Abstract (en)
[origin: EP3053927A1] The invention relates to polymorphic forms of the drug substance (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5a]pyridine-3-yl)-1H-imidazo(4,5-b]pyridine-3(2H)-yl)piperidin-1-yl)-3-oxopropanenitrile of the formula (I) and their use as therapeutic agents for the treatment of respiratory diseases.
IPC 8 full level
C07D 519/00 (2006.01); A61K 31/437 (2006.01); A61P 11/06 (2006.01)
CPC (source: CN EP US)
A61K 47/26 (2013.01 - US); A61P 11/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); C07D 519/00 (2013.01 - CN EP US); C07B 2200/13 (2013.01 - CN EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 3053927 A1 20160810; CA 2972977 A1 20160811; CA 2972977 C 20190409; CN 107207533 A 20170926; CN 107207533 B 20190416; DK 3253769 T3 20190527; EP 3253769 A1 20171213; EP 3253769 B1 20190313; ES 2722074 T3 20190807; HU E043089 T2 20190828; JP 2018502929 A 20180201; JP 2019065051 A 20190425; JP 6685326 B2 20200422; PL 3253769 T3 20190830; PT 3253769 T 20190527; SI 3253769 T1 20190531; TR 201905766 T4 20190521; US 10087196 B2 20181002; US 10508123 B2 20191217; US 2018016284 A1 20180118; US 2019031687 A1 20190131; WO 2016124464 A1 20160811
DOCDB simple family (application)
EP 15153961 A 20150205; CA 2972977 A 20160127; CN 201680008418 A 20160127; DK 16701774 T 20160127; EP 16701774 A 20160127; EP 2016051691 W 20160127; ES 16701774 T 20160127; HU E16701774 A 20160127; JP 2017557497 A 20160127; JP 2019017739 A 20190204; PL 16701774 T 20160127; PT 16701774 T 20160127; SI 201630228 T 20160127; TR 201905766 T 20160127; US 201615547657 A 20160127; US 201816113564 A 20180827